ABSTRACT
BACKGROUND AND OBJECTIVES: Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL. MATERIAL AND METHOD: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals. RESULTS: A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported. CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.
Subject(s)
Bexarotene , Mycosis Fungoides , Sezary Syndrome , Skin Neoplasms , Tetrahydronaphthalenes , Humans , Bexarotene/therapeutic use , Male , Female , Aged , Retrospective Studies , Middle Aged , Aged, 80 and over , Skin Neoplasms/drug therapy , Adult , Tetrahydronaphthalenes/therapeutic use , Tetrahydronaphthalenes/adverse effects , Mycosis Fungoides/drug therapy , Sezary Syndrome/drug therapy , Spain , Lymphoma, T-Cell, Cutaneous/drug therapy , Treatment Outcome , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effectsABSTRACT
BACKGROUND AND OBJECTIVES: Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL. MATERIAL AND METHOD: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals. RESULTS: A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported. CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.
Subject(s)
Bexarotene , Mycosis Fungoides , Sezary Syndrome , Skin Neoplasms , Tetrahydronaphthalenes , Humans , Bexarotene/therapeutic use , Male , Female , Aged , Retrospective Studies , Middle Aged , Aged, 80 and over , Skin Neoplasms/drug therapy , Adult , Tetrahydronaphthalenes/therapeutic use , Tetrahydronaphthalenes/adverse effects , Mycosis Fungoides/drug therapy , Sezary Syndrome/drug therapy , Spain , Lymphoma, T-Cell, Cutaneous/drug therapy , Treatment Outcome , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effectsABSTRACT
OBJECTIVE: Patients with nonmelanoma skin cancer (NMSC)-ie, basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)-have an increased risk of developing a second skin cancer. The aim of this study was to describe the frequency, incidence per 1000 person-years, and predictors of a second skin cancer in a cohort of patients with NMSC treated with Mohs micrographic surgery (MMS). MATERIAL AND METHODS: Prospective study of a national cohort of patients with NMSC who underwent MMS at 22 Spanish hospitals between July 2013 and February 2020; case data were recorded in the REGESMOHS registry. The study variables included demographic characteristics, frequency and incidence per 1000 person-years of second skin cancers diagnosed during the study period, and risk factors identified using mixed-effects logistic regression. RESULTS: We analyzed data for 4768 patients who underwent MMS; 4397 (92%) had BCC and 371 (8%) had SCC. Mean follow-up was 2.4 years. Overall, 1201 patients (25%) developed a second skin cancer during follow-up; 1013 of the tumors were BCCs (21%), 154 were SCCs (3%), and 20 were melanomas (0.4%). The incidence was 107 per 1000 person-years (95% CI, 101-113) for any cancer, 90 per 1000 person-years (95% CI, 85-96) for BCC, 14 (95% CI, 12-16) per 1000 person-years for SCC, and 2 (95% CI, 1-3) per 1000 person-years for melanoma. More men than women developed a subsequent skin cancer (738 [61%] vs 463 [39%]). The main risk factors were a history of multiple tumors before diagnosis (relative risk [RR], 4.6; 95% CI, 2.9-7.1), immunosuppression (RR, 2.1; 95% CI, 1.4-3.1), and male sex (RR, 1.6; 95% CI, 1.4-1.9). CONCLUSION: Patients have an increased risk of developing a second tumor after MMS treatment of NMSC. Risk factors are a history of multiple tumors at diagnosis, immunosuppression, and male sex.
Subject(s)
Carcinoma, Basal Cell , Carcinoma, Squamous Cell , Melanoma , Neoplasms, Basal Cell , Skin Neoplasms , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/pathology , Carcinoma, Basal Cell/surgery , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Cohort Studies , Female , Humans , Male , Melanoma/complications , Mohs Surgery , Prospective Studies , Risk Factors , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology , Skin Neoplasms/surgeryABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Nose Neoplasms/surgery , Rhinoplasty/methods , Plastic Surgery Procedures/methods , Surgical Flaps , Cartilage/transplantation , Suture TechniquesABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Eosinophilia/etiology , Folliculitis/etiology , Lymphoma, T-Cell, Cutaneous/complications , Skin Diseases, Vesiculobullous/etiology , Skin Neoplasms/complications , Monoclonal Gammopathy of Undetermined Significance/complications , Interferon-alpha/therapeutic use , CD3 Complex/analysis , CD4 Antigens/analysis , PUVA Therapy , Remission Induction , T-Lymphocyte Subsets , Tetrahydronaphthalenes/therapeutic useSubject(s)
Eosinophilia/etiology , Folliculitis/etiology , Lymphoma, T-Cell, Cutaneous/complications , Monoclonal Gammopathy of Undetermined Significance/complications , Skin Diseases, Vesiculobullous/etiology , Skin Neoplasms/complications , Bexarotene , CD3 Complex/analysis , CD4 Antigens/analysis , Eosinophilia/diagnosis , Eosinophilia/pathology , Folliculitis/diagnosis , Folliculitis/pathology , Humans , Interferon-alpha/therapeutic use , Lymphoma, T-Cell, Cutaneous/drug therapy , Male , Middle Aged , PUVA Therapy , Remission Induction , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/pathology , Skin Neoplasms/drug therapy , T-Lymphocyte Subsets/chemistry , T-Lymphocyte Subsets/immunology , Tetrahydronaphthalenes/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Mycosis Fungoides/diagnosis , Lymphoma, T-Cell, Cutaneous/diagnosis , Skin Neoplasms/diagnosis , BiopsySubject(s)
Mycosis Fungoides/pathology , Skin Neoplasms/pathology , Aged , Female , Humans , Male , Middle AgedABSTRACT
Acute generalized exanthematous pustulosis (AGEP) is a rare, severe, pustular, cutaneous reaction. We report a case in which a patient developed AGEP after the intake of 3 different antitussive agents containing dextromethorphan as the only ingredient in common.
Subject(s)
Acute Generalized Exanthematous Pustulosis/etiology , Antitussive Agents/adverse effects , Dextromethorphan/adverse effects , Acute Generalized Exanthematous Pustulosis/pathology , Adult , Diagnosis, Differential , Female , Humans , Psoriasis/diagnosisSubject(s)
Humans , Male , Female , Mycosis Fungoides/therapy , Ultraviolet Therapy , Retrospective StudiesSubject(s)
Panniculitis/diagnosis , Adult , Female , Gout/complications , Humans , Leg , Panniculitis/etiology , Skin Ulcer/diagnosis , Skin Ulcer/etiologyABSTRACT
No disponible
No disponible
Subject(s)
Humans , Female , Adult , Panniculitis/complications , Gout/complications , Hyperuricemia/complications , Allopurinol/therapeutic useABSTRACT
The nasal pyramid is frequently affected by nonmelanoma skin cancer. Sometimes the aggressiveness of tumours entails the extirpation of the mucosa, the cartilage, and the nasal skin. Reconstruction of the cartilaginous portion can be a surgical challenge. We demonstrate that titanium mesh can be an effective substitute for the cartilaginous portion of the nose in nasal reconstruction. We present five patients with nasal basal cell carcinoma who were treated by Mohs micrographic surgery. The partial loss of the cartilaginous structure was replaced by a 0.1 mm fenestrated titanium mesh. We have not observed any rejection or other complication in any of our patients. Good functional and aesthetic results have been obtained. Because of its biocompatibility, titanium mesh is a useful substitute for nasal cartilage. It avoids harvesting natural cartilage, reduces the risk of graft necrosis, and prevents morbidity in the donor area.
Subject(s)
Carcinoma, Basal Cell/surgery , Nose Neoplasms/surgery , Rhinoplasty/methods , Surgical Mesh , Titanium , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Nose Deformities, Acquired/surgery , Surgical Flaps , Treatment OutcomeABSTRACT
La alopecia frontal fibrosante posmenopáusica es una variante clínica diferenciada del liquen plano pilaris que afecta a mujeres de edad avanzada. Kossard describió esta alteración en 1994 como una recesión progresiva de la línea de implantación del pelo en la zona frontal, recesión que frecuentemente afecta a las cejas con alopecia cicatricial. No tiene un tratamiento efectivo, pero frecuentemente se estabiliza con el tiempo (AU)
Progressive frontal fibrosing alopecia is a clinically distinct variant of lichen planopilaris, which affects elderly women. This condition was described in postmenopausal women by Kossard in 1994 as progressive frontal hairline recession associated with scarring and frequently involving the eyebrows. No effective treatment has emerged for this condition but the alopecia may stabilize with time (AU)
